Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.
Breast Cancer Res. 2020 May 15;22(1):48. doi: 10.1186/s13058-020-01280-z.
Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
J Pharmacokinet Pharmacodyn. 2020 Feb;47(1):5-18. doi: 10.1007/s10928-019-09663-2. Epub 2019 Nov 2
CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.
Theranostics. 2019 Oct 18;9(26):8221-8238. doi: 10.7150/thno.37513. eCollection 2019.
Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform
MAbs. 2019 May 3:1-15. doi: 10.1080/19420862.2019.1596514
Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor
Int J Cancer. 2018 Feb 13
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses
JAMA Oncol. Published online February 8, 2018. doi:10.1001/jamaoncol.2017.5245
Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms.
Mol Cancer Ther. 2017 Dec;16(12):2780-2791
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
J Natl Cancer Inst. 2017 Nov 1;109(11)